Skip to main content
ROIV logo

ROIV · Roivant Sciences Ltd. · Webcasts, Transcripts & Audio

Track ROIV — free
Market Cap
$28.64B
Shares
724.56M
Volume · Nov 16 1.73M Avg daily vol (3M) 8.07M

Roivant Sciences Ltd. Webcasts

Earnings calls, investor updates, investor days and conferences for Roivant Sciences Ltd. (ROIV), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Capital Markets Day
Investor event
2026-12-09
Roivant Sciences Ltd. (ROIV) December 9, 2026 Capital Markets Day
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Roivant Sciences Ltd. (ROIV) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q2
2026-11-09
Roivant Sciences Ltd. (ROIV) Q2 2027 Earnings Call Transcript
Confident tone IMVG-1402 rheumatoid arthritis results Mosley-Sigawat PHILD program NIU clinical program
Revenue
$35.12M
▲ 2135.6% YoY
Diluted EPS
$-0.27
Gross margin
90.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-22
Roivant Sciences Ltd. (ROIV) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Roivant Sciences Ltd. (ROIV) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Roivant Sciences Ltd. (ROIV) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q1
2026-08-06
Roivant Sciences Ltd. (ROIV) Q1 2027 Earnings Call Transcript
Confident tone Pipeline catalysts and second-half data IMVT-1402 FcRn program (Graves, MG, CIDP) Cutaneous sarcoidosis phase 3
Revenue
$1.44M
▼ 33.5% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Roivant Sciences Ltd. (ROIV) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Roivant Sciences Ltd. (ROIV) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-29
Roivant Sciences Ltd. (ROIV) May 29, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q4
2026-05-20
Roivant Sciences Ltd. (ROIV) Q4 2026 Earnings Call Transcript
Confident tone Period 2 randomized withdrawal readout Mosliciguat PH-ILD Phase 2B Commercial launch execution
Revenue
$2.52M*
▼ 66.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-05-13
Roivant Sciences Ltd. (ROIV) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-02-06
Roivant Sciences Ltd. (ROIV) Q3 2026 Earnings Call Transcript
Confident tone BREPO Phase 2 data in cutaneous sarcoidosis Competitive landscape vs Argenix in Graves/TED Graves' disease program and launch readiness
Revenue
$2.00M
▼ 77.8% YoY
Diluted EPS
$-0.38
▼ 265.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2025-11-10
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Confident tone Batoclimab/1402 in Graves' disease TED and competitive landscape Late-stage pipeline and upcoming readouts
Revenue
$1.57M
▼ 64.9% YoY
Diluted EPS
$-0.17
Gross margin
92.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-08-11
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call
Revenue
$2.17M
▼ 72.8% YoY
Diluted EPS
$-0.33
▼ 375% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-05-29
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Confident tone Batoclimab / TED program failure Period 2 randomized withdrawal and placebo 1402 / DGTRA open-label data
Revenue
$7.57M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-02-10
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Confident tone Brepocitinib registrational programs and upcoming milestones Pipeline catalysts and 2026 catalysts Graves' disease launch and competitive landscape
Revenue
$9.02M
▼ 42.1% YoY
Diluted EPS
$0.23
▼ 96.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-11-12
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Confident tone IMVT-1402 across multiple indications Graves' disease and batoclimab/1402 strategy Brepocitinib VALOR data in dermatomyositis
Revenue
$4.47M
▲ 22.7% YoY
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-08-08
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Revenue
$7.99M
▼ 63.1% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-05-30
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call
Revenue
−$8.12M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-02-13
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Confident tone Indication selection strategy for brepasitinib Catalysts and milestones in 2025 Pipeline breadth and BD activity
Revenue
$15.56M
▼ 8.7% YoY
Diluted EPS
$6.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2023-11-13
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Revenue
$3.65M
▼ 70.9% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-08-14
Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript
Revenue
$21.62M
▲ 400.7% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-06-28
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
Revenue
−$2.37M*
▼ 125.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-02-01
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Revenue
$17.05M
▼ 29.9% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2022-11-14
Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
Revenue
$12.53M
▼ 10.4% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-08-15
Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript
Revenue
$4.32M
▼ 44.2% YoY
Diluted EPS
$-0.48
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-06-28
Roivant Sciences Ltd. (ROIV) Q4 2022 Earnings Call Transcript
Revenue
$9.22M*
▼ 39.1% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-02-14
Roivant Sciences Ltd. (ROIV) Q3 2022 Earnings Call Transcript
Revenue
$24.34M
▲ 323.3% YoY
Diluted EPS
$-0.41
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2021-11-15
Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Call Transcript
Revenue
$13.99M
▲ 957.2% YoY
Diluted EPS
$-0.32
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-09-21
Roivant Sciences Ltd. (ROIV) Q1 2022 Earnings Call Transcript
Revenue
$7.74M
▲ 390.8% YoY
Diluted EPS
$-0.13
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2020-09-30
Date not confirmed
Roivant Sciences Ltd. (ROIV) Q2 2021 Earnings Call Transcript
Revenue
$1.32M
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–32 of 32 webcasts
Key facts CIK 1635088 CUSIP G76279101 13F (30d) 387 filings 351 filers Visit website Investor relations